Literature DB >> 32736212

Bioisosteric substitution of adamantane with bicyclic lipophilic groups improves water solubility of human soluble epoxide hydrolase inhibitors.

Vladimir Burmistrov1, Christophe Morisseau2, Dmitry Karlov3, Dmitry Pitushkin4, Andrey Vernigora5, Elena Rasskazova5, Gennady M Butov6, Bruce D Hammock7.   

Abstract

A series of inhibitors of the soluble epoxide hydrolase (sEH) containing lipophilic groups of natural origin (camphanyl, norcamphanyl, furan-2-yl) were developed. Inhibitory potency ranging from 0.4 nM to 2.16 μM were obtained. While having the same level of inhibitory activity bicyclic ureas are up to 10-fold more soluble than the corresponding ureas containing adamantyl or 4-trifluoromethoxyphenyl substituents. This makes them easier to formulate, more bioavailable and thus more promising as therapeutic sEH inhibitors. Endo/exo-form of compound 2b derived from l-camphor is 14-fold more potent than the corresponding analogue derived from d-camphor (IC50 = 3.7 nM vs. 50.6 nM) indicating enantiomeric preference.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adamantane; Camphor; Inhibitor; Norcamphane; Soluble epoxide hydrolase; Urea

Mesh:

Substances:

Year:  2020        PMID: 32736212      PMCID: PMC7494652          DOI: 10.1016/j.bmcl.2020.127430

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  16 in total

1.  Symmetric adamantyl-diureas as soluble epoxide hydrolase inhibitors.

Authors:  Vladimir Burmistrov; Christophe Morisseau; Kin Sing Stephen Lee; Diyala S Shihadih; Todd R Harris; Gennady M Butov; Bruce D Hammock
Journal:  Bioorg Med Chem Lett       Date:  2014-03-20       Impact factor: 2.823

2.  An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension.

Authors:  John D Imig; Xueying Zhao; Constantine Z Zaharis; Jeffrey J Olearczyk; David M Pollock; John W Newman; In-Hae Kim; Takaho Watanabe; Bruce D Hammock
Journal:  Hypertension       Date:  2005-09-12       Impact factor: 10.190

3.  Effects of adamantane alterations on soluble epoxide hydrolase inhibition potency, physical properties and metabolic stability.

Authors:  Vladimir Burmistrov; Christophe Morisseau; Todd R Harris; Gennady Butov; Bruce D Hammock
Journal:  Bioorg Chem       Date:  2017-12-30       Impact factor: 5.275

4.  Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase.

Authors:  Paul D Jones; Hsing-Ju Tsai; Zung N Do; Christophe Morisseau; Bruce D Hammock
Journal:  Bioorg Med Chem Lett       Date:  2006-07-25       Impact factor: 2.823

5.  Pharmacokinetics and in vivo potency of soluble epoxide hydrolase inhibitors in cynomolgus monkeys.

Authors:  A Ulu; Se Appt; C Morisseau; S H Hwang; P D Jones; T E Rose; H Dong; J Lango; J Yang; H J Tsai; C Miyabe; C Fortenbach; M R Adams; B D Hammock
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 6.  Humble beginnings with big goals: Small molecule soluble epoxide hydrolase inhibitors for treating CNS disorders.

Authors:  Sydney Zarriello; Julian P Tuazon; Sydney Corey; Samantha Schimmel; Mira Rajani; Anna Gorsky; Diego Incontri; Bruce D Hammock; Cesar V Borlongan
Journal:  Prog Neurobiol       Date:  2018-11-14       Impact factor: 11.685

7.  Sequence similarity of mammalian epoxide hydrolases to the bacterial haloalkane dehalogenase and other related proteins. Implication for the potential catalytic mechanism of enzymatic epoxide hydrolysis.

Authors:  M Arand; D F Grant; J K Beetham; T Friedberg; F Oesch; B D Hammock
Journal:  FEBS Lett       Date:  1994-02-07       Impact factor: 4.124

8.  Epoxyeicosatrienoic acids regulate Trp channel dependent Ca2+ signaling and hyperpolarization in endothelial cells.

Authors:  Ingrid Fleming; Alexandra Rueben; Rüdiger Popp; Beate Fisslthaler; Susanne Schrodt; Anna Sander; Judith Haendeler; John R Falck; Christophe Morisseau; Bruce D Hammock; Rudi Busse
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-09-13       Impact factor: 8.311

9.  Orally bioavailable potent soluble epoxide hydrolase inhibitors.

Authors:  Sung Hee Hwang; Hsing-Ju Tsai; Jun-Yan Liu; Christophe Morisseau; Bruce D Hammock
Journal:  J Med Chem       Date:  2007-07-06       Impact factor: 7.446

10.  Structure-activity relationships of amide-phosphonate derivatives as inhibitors of the human soluble epoxide hydrolase.

Authors:  In-Hae Kim; Yong-Kyu Park; Hisashi Nishiwaki; Bruce D Hammock; Kosuke Nishi
Journal:  Bioorg Med Chem       Date:  2015-10-22       Impact factor: 3.641

View more
  2 in total

1.  Movement to the Clinic of Soluble Epoxide Hydrolase Inhibitor EC5026 as an Analgesic for Neuropathic Pain and for Use as a Nonaddictive Opioid Alternative.

Authors:  Bruce D Hammock; Cindy B McReynolds; Karen Wagner; Alan Buckpitt; Irene Cortes-Puch; Glenn Croston; Kin Sing Stephen Lee; Jun Yang; William K Schmidt; Sung Hee Hwang
Journal:  J Med Chem       Date:  2021-02-07       Impact factor: 7.446

Review 2.  Small Molecule Soluble Epoxide Hydrolase Inhibitors in Multitarget and Combination Therapies for Inflammation and Cancer.

Authors:  Amarjyoti Das Mahapatra; Rinku Choubey; Bhaskar Datta
Journal:  Molecules       Date:  2020-11-24       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.